Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - Subgroup data from a randomised multinational trial GWAA

Endokrynologia Polska

Volumn 64, Issue 5, 2013, Pages 375-382

  Matyjaszek Matuszek, Beata ^a   Lenart Lipińska, Monika ^a   Rogalska, Dorota ^b   Nowakowski, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Eli Lilly Polska Sp z oo   (Poland)

Author keywords

Exenatide; GLP 1 agonist; Insulin glargine; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN; PEPTIDE; SULFONYLUREA DERIVATIVE; VENOM;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POLAND; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; NAUSEA; PEPTIDES; SULFONYLUREA COMPOUNDS; VENOMS; VOMITING;

EID: 84888876659     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2013.0021     Document Type: Article

References (47)

1. Weyer C, Bogardus C, Mott DM et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
2. Butler AE, Janson J, Bonner-Weir S et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-10.
3. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
5. Creutzfeldt W. Entero-insular axis and diabetes mellitus. Horm Metab Res Suppl 1992; 26: 13-18.
6. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-206.
7. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide response. J Clin Endocrinol Metab 1989; 63: 492-498.
8. Knop FK, Vilsbøll T, Højberg PV et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959.
9. Matuszek B, Lenart-Lipińska M, Nowakowski A. Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins - new possibilities for pharmacotherapy of type 2 diabetes. Endokrynol Pol 2008; 59: 322-329.
10. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetes patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
11. Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol (Oxf) 2012; 77: 489-499.
12. Nauck MA, Sauerwald A, Ritzel R et al. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21: 1925-1931.
13. Zander M, Madsbad S, Madsen JL et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
14. Hinnen D, Nielsen LL, Waninger A et al. Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 2006; 19: 612-620.
15. Martin JH, Deacon CF, Gorrell MD et al. Incretin - based therapiesreview of the physiology, pharmacology and emerging clinical experience. Intern Med J 2011; 41: 299-307.
16. Ahrén B. GLP-1 for type 2 diabetes. Exp Cell Res 2011; 317: 1239-1245.
17. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
18. Blevins T, Han J, Nicewarner D et al. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 2010; 122: 118-128.
19. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7.
20. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286.
21. Davis SN, Johns D, Maggs D et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007; 30: 2767-2772.
22. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-2348.
23. Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia 2006; 50: 259-267.
24. Klein S, Sheard NF, Pi-Sunyer X et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: 2067-2073.
25. Polskie Towarzystwo Diabetologiczne. Zalecenia kliniczne dotyczace postepowania u chorych na cukrzyce, 2012. Diabetologia Kliniczna 2012; 1 (Suppl. A).
26. Peters AL. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med 2009; 76(Suppl. 5): S20-27.
27. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011; 108 (3 Suppl.): 33B-41B.
28. Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11: 1163-72.
29. Bunck MC, Diamant M, Eliasson B et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010; 33: 1734-1737.
30. Nielsen LL, Okerson T, Holcombe J et al. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2: 255-260.
31. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
32. Kendall DM, Kim D, Poon T et al. Improvement in cardiovascular risk factor accompanied sustained effects on glycaemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Diabetes 2005; 54 (Suppl. 1): A4-A5.
33. Navarro M, Rodriguez de Fonseca F, Alvarez E et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2 and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996; 67: 1982-1991.
34. Al-Barazanji KA, Arch JR, Buckingham RE et al. Central exendin-4 infusion reduced body weight without altering plasma leptin in(fa/fa) Zucker rats. Obes Res 2000; 8: 317-323.
35. Mack CM, Moore CX, Jodka CM et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332-1340.
36. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122: S3-S10.
37. Nagell CF, Wattergren A, Orskov C et al. Inhibitory effect of GLP-1 on gastric motililty persists effect vagal deafferentiation in pigs. Scand J Gastroenterolog 2006; 41: 667-672.
38. Talsania T, Anini Y, Siu S et al. Peripheral exendin-4 and peptide 44 (3-36) synergistically reduce fodd intake through different mechanisms in mice. Endocrinology 2005; 146: 3748-3756.
39. D'Alessio DA, Sandoval DA, Seeley RJ. New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest 2005; 115: 3406-3408.
40. Linnebjerg H, Park S, Kothare PA et al. Effect of exenatide on gastric emptying and relationship to posprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
41. Mojtahedzadeh M, Jafarieh A, Najafi A et al. Comparison of metformin and insulin in the control of hyperglycaemia in non-diabetic critically ill patients. Endokrynol Pol 2012; 63: 206-211.
42. Exenatide (Summary of Product Characteristics). Houten, The Netherlands: Eli Lilly Nederland BV; 2012.
43. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912.
44. Cvetković RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67: 935-954.
45. Gentilella R, Bianchi C, Rossi A et al. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 2009; 11: 544-556.
46. ltz JL, Baker DE, Setter SM et al. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006; 28: 652-665.
47. Robles GI, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 2009; 3: 219-240.